B6 mothers were mated with CD45.1 fathers, and the CD45.1+/CD45.2+ fetuses were injected with allogeneic NOD.CD45.1 FL cells or PBS on E14.5. Injected (and uninjected control) fetuses were sacrificed on E18.5–E19.5, and the number of maternal leukocytes (CD45.2+) in fetal blood was quantified. (A) Flow cytometric analysis of donor (gate D), maternal (gate M), and fetal (gate F) leukocytes. (B) Frequency of fetuses with circulating maternal leukocytes (number of fetuses with circulating maternal leukocytes/total number of fetuses) after PBS injection (n = 11/33, 33%) and allogeneic FL injection (n = 12/21, 57%) and in age-matched uninjected controls (n = 0/21, 0%). (C) Percentage of maternal leukocytes (CD45.2+ maternal leukocytes/total CD45.2+ cells) in fetal circulation after PBS (n = 11) and allogeneic FL injection (n = 12). (D) Lineage analysis of trafficking maternal cells shown as percentage of maternal leukocytes (e.g., trafficked maternal Gr-1+ cells/total trafficked maternal leukocytes). *P < 0.005, **P < 0.0001 by t test. (E) Lineage analysis of trafficking maternal cells shown as the percentage of maternal cells contributing to each of the leukocyte subsets in fetal circulation (e.g., trafficked maternal Gr-1+ cells/total number of fetal and trafficked maternal Gr-1+ cells). *P < 0.05 by t test.